Tier 4 — mechanistic

Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs

M. D'Altilio, A. Peal, M. Alvey, C. Simms, A. Curtsinger, R.C. Gupta, T.D. Canerdy, J.T. Goad, M. Bagchi, D. Bagchi
Toxicology Mechanisms and Methods 2007 17(4):189-196

Bibliography

PubMed
PMID 20020968
DOI
10.1080/15376510600910469
Funding
The authors would like to thank InterHealth Nutraceuticals Inc. for their support in carrying out this investigation. Biohack Blueprint assessment: two co-authors (M. Bagchi, D. Bagchi) are affiliated with InterHealth Nutraceuticals Inc., the manufacturer of the UC-II ingredient tested and the study's funder — the same company and product category as lugo-2016-uc-ii-knee-osteoarthritis, elsewhere in this Data Center.
Competing interests
Not formally disclosed as a separate statement; see funding field for affiliation-based conflicts and manufacturer support.

Study snapshot

DesignRandomised, double-blind, placebo-controlled animal (canine) trial
ModelClient-owned adult dogs with clinical signs of moderate arthritis (joint stiffness, lameness, pain)
Samplen=20 dogs in 4 groups of n=5: placebo; UC-II 10 mg/day; glucosamine 2000 mg + chondroitin 1600 mg/day; UC-II + glucosamine + chondroitin combined
InterventionGlycosylated undenatured type II collagen (UC-II), 10 mg/day, alone or combined with glucosamine HCl (2000 mg/day) and chondroitin sulfate (1600 mg/day), given daily for 120 days, followed by a 30-day withdrawal. This is a microgram-scale dose of a structurally undenatured collagen protein administered to dogs, not hydrolysed collagen peptides administered to humans.
Duration120 days of treatment, followed by a 30-day withdrawal period, with pain assessments through day 150
EndpointsOverall pain (0–10 scale, gross observation); Pain upon limb manipulation (0–4 scale); Exercise-associated lameness (0–4 scale); Serum markers of liver (ALT, bilirubin) and renal/heart function (BUN, creatinine); Body weight

What the study showed, in plain terms

This is a veterinary study, not a human trial, and it tests a different ingredient from the hydrolysed collagen peptides covered elsewhere on this site: undenatured type II collagen (UC-II), given to arthritic dogs at a 10 mg daily dose.

Over 120 days, dogs receiving UC-II alone showed substantial reductions in owner/veterinarian-rated pain — up to 62% reduction in overall pain, 91% in pain upon limb manipulation, and 78% in exercise-associated lameness by day 120 — clearly outperforming glucosamine plus chondroitin alone. All treated dogs relapsed once supplementation was withdrawn for 30 days.

This paper is included in the Data Center purely as a differentiation reference: it demonstrates the same UC-II ingredient and InterHealth Nutraceuticals sponsorship seen in the lugo-2016 human knee osteoarthritis trial, but here in a small, industry-funded, animal pain-scoring study that has no direct bearing on hydrolysed collagen peptide products.

Key findings

  • UC-II alone produced significant reductions in overall pain within 30 days (33%), with maximum reductions at 120 days (overall pain −62%; pain on limb manipulation −91%; exercise-associated lameness −78%).
  • Glucosamine plus chondroitin alone alleviated some pain but not significantly (p>0.05).
  • The combination of UC-II with glucosamine and chondroitin performed significantly better than glucosamine and chondroitin alone, though somewhat less well than UC-II alone on these outcome measures.
  • All treated dogs (UC-II, glucosamine+chondroitin, and the combination) relapsed in pain and lameness following a 30-day supplement withdrawal.
  • No adverse effects were observed in any group; liver (ALT, bilirubin) and renal/heart (BUN, creatinine) markers, and body weight, remained stable throughout.

What this study can and cannot tell us

  • Animal (canine) model, not a human trial — findings cannot be extrapolated to human collagen supplementation, and especially not to hydrolysed collagen peptides, a structurally and mechanistically distinct ingredient.
  • Very small sample size (n=5 per group, n=20 total).
  • Pain outcomes were gross behavioural/observational scores rated by investigators and owners rather than validated, blinded instrumental measures.
  • Two co-authors are employees of InterHealth Nutraceuticals, the manufacturer of the UC-II ingredient tested and the study's funder, a direct financial conflict of interest.
  • Tests UC-II at a microgram dose via a proposed oral-tolerance immune mechanism — mechanistically unrelated to gram-scale hydrolysed collagen peptide supplementation.

Related papers in the corpus

Tier 2
Efficacy and Tolerability of an Undenatured Type II Collagen Supplement in Modulating Knee Osteoarthritis Symptoms: A Multicenter Randomized, Double-Blind, Placebo-Controlled Study
James P. Lugo et al. · Nutrition Journal · 2016
Tier 2
Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis
David E. Trentham et al. · Science · 1993

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology